For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
How does the forecasted CAGR of the chronic pulmonary hypertension treatment industry compare to other sectors?
The chronic pulmonary hypertension treatment market size has grown strongly in recent years. It will grow from $6.82 billion in 2024 to $7.21 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing prevalence of chronic pulmonary hypertension, increasing drug approval, favorable reimbursement policies, rising healthcare expenditure, aging population.
The chronic pulmonary hypertension treatment market size is expected to see strong growth in the next few years. It will grow to $8.95 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to growing demand for effective treatments, increasing investments, increase in government support for drug development, growing demand for advanced therapeutics, increasing awareness, increasing incidence of chronic brain injuries. Major trends in the forecast period include development of new drugs and therapies, advancements in technology, collaboration with pharmaceutical companies, research institutions, and healthcare organizations, identifying new molecular pathways, governments and healthcare organizations investments, innovation of new therapies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21148&type=smp
What market trends are acting as primary growth drivers for the chronic pulmonary hypertension treatment sector?
The high burden of cardiovascular diseases is expected to propel the growth of the chronic pulmonary hypertension treatment market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The high burden of cardiovascular diseases is attributed to risk factors such as unhealthy diets, physical inactivity, tobacco use, excessive alcohol consumption, obesity, hypertension, diabetes, and aging populations. Chronic pulmonary hypertension treatment supports cardiovascular health by lowering pulmonary artery pressure, enhancing heart function, and reducing the risk of heart failure and related complications. For instance, in December 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, there were 14,100 doctor-certified deaths attributed to coronary heart disease (CHD) in 2021, rising to 14,900 in 2022. Therefore, the high burden of cardiovascular diseases is driving the growth of the chronic pulmonary hypertension treatment market.
What are the fastest-growing segments in the chronic pulmonary hypertension treatment market forecast period?
The chronic pulmonary hypertension treatment market covered in this report is segmented –
1) By Drug Type: Endothelin Receptor Antagonists, Phosphodiesterase (PDE-5) Inhibitors, Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators
2) By Route Of Administration: Oral, Intravenous Or Subcutaneous, Inhalational
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Endothelin Receptor Antagonists: Bosentan, Ambrisentan, Macitentan
2) By Phosphodiesterase (PDE-5) Inhibitors: Sildenafil, Tadalafil, Vardenafil
3) By Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By Soluble Guanylate Cyclase (SGC) Stimulators: Riociguat
View The Full Market Report:
What technological trends are expected to redefine the chronic pulmonary hypertension treatment market?
Major companies operating in the chronic pulmonary hypertension treatment market are focusing on innovative solutions, such as subcutaneous injection, to enhance patient compliance, improve convenience, and provide more targeted treatment options. Subcutaneous injection delivers continuous medication under the skin to help lower pulmonary artery pressure and improve blood flow in pulmonary hypertension patients. For instance, in March 2024, Merck & Co Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Winrevair (sotatercept-csrk), marking a significant advancement in pulmonary arterial hypertension (PAH) treatment. This innovative therapy offers unique benefits, distinguishing it as a groundbreaking option for PAH. Clinical trials have demonstrated that Winrevair improves WHO functional class in 29% of patients, compared to 14% in the placebo group, leading to an overall enhancement in quality of life.
Which major players hold significant market share in the chronic pulmonary hypertension treatment sector?
Major companies operating in the chronic pulmonary hypertension treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, GSK (GlaxoSmithKline), Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Insmed, Cereno Scientific, Roivant Sciences, LGM Pharma, Liquidia Technologies
Which regional segments are forecasted to witness the fastest growth in the chronic pulmonary hypertension treatment market?
North America was the largest region in the chronic pulmonary hypertension treatment market in 2024. The regions covered in the chronic pulmonary hypertension treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Chronic Pulmonary Hypertension Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21148
Need Customized Data On Chronic Pulmonary Hypertension Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=21148&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
